drugset / Trial / NCT05810103
A Study of DP303c in Patients With HER2-positive Advanced Solid Tumors
NaSingle-groupOpen-labelTreatment
Summary
This is a study of DP303c in patients with HER2-positive advanced solid tumors.
Timeline
- Start
- 2023-04-06
- Primary completion
- 2023-12-23
- Completion
- 2024-03-23
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | TRASTUZUMAB ENVEDOTIN | Monoclonal antibody | 3 mg/kg | — |